Sign in
CAPR Stock Price, Chart, Stats & News
Capricor Therapeutics, Inc.
Save
1.30B
Market cap
–
Current P/E
78.74x
Forward P/E
CAPR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -29.51% |
ROE | -67.52% |
D/E | 0.07x |
Interest coverage ratio | -35.51x |
CAPR valuation
P/E | – |
P/S | – |
P/B | 4.62x |
P/CF | -20.22x |
P/FCF | -16.20x |
P/OCF | -20.22x |
PEG | 0.53x |
EV multiple | -15.12x |
About
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD).
Similar securities
Based on sector and market capitalization
Report issue